Merck & Co. Inc.'s victory with its PD-1 inhibitor Keytruda showing an overall survival benefit in the KEYNOTE-189 first-line metastatic non-small cell lung cancer study shows once again that the company has a knack for getting it right in the most important immuno-oncology indications.
The KEYNOTE-189 study tested Keytruda (pembrolizumab) with Eli Lilly & Co.'s Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy versus Alimta and cisplatin or carboplatin in 614 patients who had...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?